Yeast-based automated high-throughput screens to identify anti-parasitic lead compounds

Open Biology

Volumn 3, Issue FEB, 2013, Pages

  Bilsland, Elizabeth ^a   Sparkes, Andrew ^b   Williams, Kevin ^b   Moss, Harry J ^a   De Clare, Michaela ^a   Pir, Pinar ^a   Rowland, Jem ^b   Aubrey, Wayne ^c   Pateman, Ron ^b   Young, Mike ^e   Carrington, Mark ^a   King, Ross D ^d   Oliver, Stephen G ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ABERYSTWYTH UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e ABERYSTWYTH UNIVERSITY   (United Kingdom)

Author keywords

Automation; Drug screening; Parasites; Tropical diseases; Yeast

Indexed keywords

ANTIPARASITIC AGENT; LEAD; MOLECULAR LIBRARY;

CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR LIBRARY; PATHOLOGY; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN; YEAST; AFRICAN TRYPANOSOMIASIS; ARTICLE; DRUG EFFECT; TRYPANOSOMA BRUCEI;

ANTIPARASITIC AGENTS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEAD; SMALL MOLECULE LIBRARIES; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN; YEASTS;

EID: 84877766285     PISSN: None     EISSN: 20462441     Source Type: Journal    
DOI: 10.1098/rsob.120158     Document Type: Article

References (45)

1. World Health Organization. 2011 World malaria report: 2011. See http://www.who.int/malaria/world-malaria-report-2011/en.
2. Sibley CH, Ringwald P. 2006 A database of antimalarial drug resistance. Malar. J. 5, 48. (doi:10.1186/1475-2875-5-48) (Pubitemid 44211710)
3. Lexchin J. 2010 One step forward, one step sideways? Expanding research capacity for neglected diseases. BMC Int. Health Hum. Rights 10, 20. (doi:10.1186/1472-698X-10-20)
4. Zucca M, Savoia D. 2011 Current developments in the therapy of protozoan infections. Open Med. Chem. J. 5, 4-10. (doi:10.2174/1874104501105010004/TOMCJ- 5-4)
5. Pink R, Hudson A, Mouries MA, Bendig M. 2005 Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov. 4, 727-740. (doi:10.1038/nrd1824) (Pubitemid 43090494)
6. Don R, Chatelain E. 2009 Drug discovery for neglected diseases: view of a public-private partnership. In Antiparasitic and antibacterial drug discovery: from molecular targets to drug candidates (ed. PM Selzer), pp. 33-43. Weinhei, Germany: WILEY-VCH Verlag.
7. Lefevre G, Marrast AC, Grueninger H. 2011 Novartis malaria initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria. Ann. NY Acad. Sci. 1222, 19-29. (doi:10.1111/j.1749-6632.2011. 05973.x)
8. Ekins S, Williams AJ. 2010 When pharmaceutical companies publish large datasets: an abundance of riches or fool's gold? Drug Discov. Today 15, 812-815. (doi:10.1016/j.drudis.2010.08.010)
9. Peak E, Chalmers IW, Hoffmann KF. 2010 Development and validation of a quantitative, highthroughput, fluorescent-based bioassay to detect schistosoma viability. PLoS Negl. Trop. Dis. 4, e759. (doi:10.1371/journal.pntd.0000759)
10. Smout MJ, Kotze AC, McCarthy JS, Loukas A. 2010 A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility. PLoS Negl. Trop. Dis. 4, e885. (doi:10.1371/journal.pntd.0000885)
11. Pillai AD, Pain M, Solomon T, Bokhari AA, Desai SA. 2010 A cell-based high-throughput screen validates the plasmodial surface anion channel as an antimalarial target. Mol. Pharmacol. 77, 724-733. (doi:10.1124/mol.109.062711)
12. Gupta S. 2011 Visceral leishmaniasis: experimental models for drug discovery. Indian J. Med. Res. 133, 27-39.
13. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. 2009 Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect. Dis. 9, 555-566. (doi:10.1016/S1473- 3099(09) 70177-X)
14. Sattabongkot J, Yimamnuaychoke N, Leelaudomlipi S, Rasameesoraj M, Jenwithisuk R, Coleman RE, Udomsangpetch R, Cui L, Brewer TG. 2006 Establishment of a human hepatocyte line that supports in vitro development of the exoerythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am. J. Trop. Med. Hyg. 74, 708-715. (Pubitemid 46774383)
15. Barberis A, Gunde T, Berset C, Audetat S, Luthi U. 2005 Yeast as a screening tool. Drug Discov. Today 2, 187-192. (doi:10.1016/j.ddtec. 2005.05.022) (Pubitemid 40946327)
16. Bertino JR. 2009 Cancer research: from folate antagonism to molecular targets. Best Pract. Res. Clin. Haematol. 22, 577-582. (doi:10.1016/j.beha.2009. 09.004)
17. Certain LK, Sibley CH. 2007 Plasmodium falciparum: a novel method for analyzing haplotypes in mixed infections. Exp. Parasitol. 115, 233-241. (doi:10.1016/j.exppara.2006.09.003) (Pubitemid 44828060)
18. Rungsihirunrat K, Na-Bangchang K, Hawkins VN, Mungthin M, Sibley CH. 2007 Sensitivity to antifolates and genetic analysis of Plasmodium vivax isolates from Thailand. Am. J. Trop. Med. Hyg. 76, 1057-1065. (Pubitemid 351837866)
19. Sibley CH, Brophy VH, Cheesman S, Hamilton KL, Hankins EG, Wooden JM, Kilbey B. 1997 Yeast as a model system to study drugs effective against apicomplexan proteins. Methods 13, 190-207. (doi:10.1006/meth.1997.0511) (Pubitemid 28033517)
20. Michels PA, Bringaud F, Herman M, Hannaert V. 2006 Metabolic functions of glycosomes in trypanosomatids. Biochim. Biophys. Acta 1763, 1463-1477. (doi:10.1016/j.bbamcr.2006.08.019) (Pubitemid 44880465)
21. Murabito E, Smallbone K, Swinton J, Westerhoff HV, Steuer R. 2010 A probabilistic approach to identify putative drug targets in biochemical networks. J. R. Soc. Interface 8, 880-895. (doi:10.1098/rsif.2010.0540)
22. Crowther GJ et al. 2011 Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol. Biochem. Parasitol. 175, 21-29. (doi:10.1016/j.molbiopara.2010.08.005)
23. Frearson JA et al. 2010 N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464, 728-732. (doi:10.1038/nature08893)
24. Mina JG, Pan SY, Wansadhipathi NK, Bruce CR, Shams-Eldin H, Schwarz RT, Steel PG, Denny PW. 2009 The Trypanosoma brucei sphingolipid synthase, an essential enzyme and drug target. Mol. Biochem. Parasitol. 168, 16-23. (doi:10.1016/j.molbiopara.2009.06.002)
25. Gamo FJ et al. 2010 Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305-310. (doi:10.1038/nature09107)
26. Nagle A et al. 2011 Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. J. Med. Chem. 55, 4244-4273. (doi:10. 1021/jm300041e)
27. Guiguemde WA et al. 2010 Chemical genetics of Plasmodium falciparum. Nature 465, 311-315. (doi:10.1038/nature09099)
28. Bilsland E, Pir P, Gutteridge A, Johns A, King RD, Oliver SG. 2011 Functional expression of parasite drug targets and their human orthologs in yeast. PLoS Negl. Trop. Dis. 5, e1320. (doi:10.1371/journal.pntd.0001320/PNTD-D- 11-00499)
29. Keppler-Ross S, Noffz C, Dean N. 2008 A new purple fluorescent color marker for genetic studies in Saccharomyces cerevisiae and Candida albicans. Genetics 179, 705-710. (doi:10.1534/genetics.108.087080)
30. Sheff MA, Thorn KS. 2004 Optimized cassettes for fluorescent protein tagging in Saccharomyces cerevisiae. Yeast 21, 661-670. (doi:10.1002/yea.1130) (Pubitemid 38868184)
31. Bilsland E et al. In preparation. Automating drug discovery.
32. King RD et al. 2009 The automation of science. Science 324, 85-89. (doi:10.1126/science.1165620)
33. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. 2011 Open Babel: an open chemical toolbox. J. Cheminformatics 3, 33. (doi:10.1186/1758-2946-3-33)
34. Rahman SA, Bashton M, Holliday GL, Schrader R, Thornton JM. 2009 Small molecule subgraph detector (SMSD) toolkit. J. Cheminformatics 1, 12. (doi:10.1186/1758-2946-1-12)
35. Weininger D. 1988 Smiles, a chemical language and information-system. I. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci. 28, 31-36. (doi:10.1021/ci00057a005) (Pubitemid 18574254)
36. Gari E, Piedrafita L, Aldea M, Herrero E. 1997 A set of vectors with a tetracycline-regulatable promoter system for modulated gene expression in Saccharomyces cerevisiae. Yeast 13, 837-848. (doi:10. 1002/(SICI)1097- 0061(199707)13:9,837::AIDYEA145.3.0.CO;2-T) (Pubitemid 27285747)
37. Sparkes A et al. 2010 Towards Robot Scientists for autonomous scientific discovery. Autom. Exp. 2, 1. (doi:10.1186/1759-4499-2-1)
38. Willett P. 2011 Similarity searching using 2D structural fingerprints. Methods Mol. Biol. 672, 133-158. (doi:10.1007/978-1-60761-839-3-5)
39. Raymond JW, Willett P. 2002 Maximum common subgraph isomorphism algorithms for the matching of chemical structures. J. Comput. Aided Mol. Des. 16, 521-533. (doi:10.1023/A:1021271615909) (Pubitemid 36013605)
40. Conteh L, Engels T, Molyneux DH. 2011 Socioeconomic aspects of neglected tropical diseases. Lancet 375, 239-247. (doi:10.1016/S0140-6736(09)61422-7)
41. Doherty M. 2011 Communication and collaboration- Influencing behaviour through effective partnership and information sharing. J. Eur. Med. Writers Assoc. 20, 146-148.
42. Ioset JR, Chang S. 2011 Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges. Future Med. Chem. 3, 1361-1371. (doi:10.4155/fmc.11.102)
43. Leslie M. 2011 Infectious diseases. Drug developers finally take aim at a neglected disease. Science 333, 933-935. (doi:10.1126/science.333.6045.933)
44. Rottmann M et al. 2010 Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175-1180. (doi:10.1126/science.1193225)
45. Marjanovic J et al. 2010 Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity. Proc. Natl Acad. Sci USA 107, 9093-9098. (doi:10.1073/pnas.1003721107)